The Latest Breaking News from Eli Lilly

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

MarketBeat · Oct 23, 2025

What Is Retatrutide? Viral Weight Loss Drug Claimed to Battle Obesity—But Is It Even Real?

Influencers are promoting the weight-loss drug Retatrutide online, but it's an unapproved medication. Learn about the dangers of fake versions and when the real drug might actually be available.

International Business Times UK · Oct 18, 2025

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly and Company (NYSE:LLY) shares are trading lower Friday, among other GLP-1 drug manufacturers, following President Donald Trump‘s comments that fat-loss drugs will be a lot lower in price.

Benzinga · Oct 17, 2025

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

MarketBeat · Oct 15, 2025

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

Benzinga · Oct 15, 2025

Don’t give in to big pharma on drug pricing

Letter: Drug manufacturers may lament the UK’s drug prices, writes Simon Dixon, but the NHS should celebrate them

The Guardian - UK · Oct 15, 2025

3 Healthcare Companies Insiders Are Buying

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

MarketBeat · Oct 14, 2025

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

Benzinga · Oct 13, 2025

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

The Guardian - UK · Oct 11, 2025

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations

Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.

Benzinga · Oct 10, 2025